Company Deep Dive

Read the full research report: business segments breakdown, earnings transcripts review, management credibility analysis, competitive landscape, and scenarios.

View Deep Dive

INVA

STRONG BUY

Innoviva, Inc. · Healthcare · United States · $1.7B · Avg Vol: $20M/d

97
StockRank
Get insider-trade alerts
Q
72
V
74
M
59
P/E (TTM)
3.6x
ROE
50.7%
D/E
0.2x
Dividend %
—
Dir. Trades · 180d
None →
Buybacks · 180d
$20.2M →

COMPANY DESCRIPTION

Innoviva, Inc. focuses on royalties from respiratory drugs, primarily through its collaboration with GlaxoSmithKline (GSK) on therapies like Relvar/Breo Ellipta and Anoro Ellipta. The company benefits from a stable, long-term revenue stream derived from royalties on blockbuster respiratory medications, minimizing operational and R&D expenditures. It is a unique healthcare company acting primarily as a royalty aggregator, providing exposure to established drug franchises.

FINANCIAL SUMMARY (USD)

Year2022202320242025CAGRTTM2026E2027EFwd CAGR
Revenue331.3M310.5M358.7M411.3M7.5%420.7M440.6M486.1M8.7%
EPS3.072.750.374.029.4%6.194.104.748.6%
Shares69.2M63.3M62.7M74.6M+7.9%73.8M———
Debt544.1M449.1M451.1M269.0M-20.9%331.4M———
Equity565.8M675.0M691.2M1.2B27.5%————
Op CF201.7M141.1M188.7M196.9M-0.8%183.6M———
Inv CF-56.6M-66.8M-63.8M40.5M—————
Fin CF-55.6M-171.8M-13.5M8.6M—————
Loading 1Y...
PRICE (1Y)+0.3%
21.3521.9222.4923.0723.64May 27Jun 17Jul 9
SMA 50SMA 200
Close
$22.20
RSI (14)
45.8
52W High
$25.15
From 52W High
0.9%

SCORE BREAKDOWN

Quality
72
ROIC
21.7%92.7
ROE
50.7%97.4
GP/Assets
19.1%45.4
Op. Margin
40.1%96.7
FCF/Assets
6.4%75.3
Piotroski
548.9
Int. Cover
20.6x69.7
D/E Ratio
0.25x48.5
Current Ratio
21.13x95.9
Value
74
P/E (TTM)
3.6x99.0
EV/EBITDA
7.0x83.6
P/FCF
16.5x69.7
P/B
1.2x77.5
P/S
3.9x48.6
Div Yield
—N/A
Momentum
59
52W High %
88%78.6
RS 6M
6%74.8
SMA 50/200
1.06x77.0
EPS Rev 4W
0.0%64.0
EPS Rev 12W
+15.7%61.8
EPS Improve
-64%6.8
Q Growth
—N/A

FUNDAMENTALS

Market Cap
$1.7B
P/E (Forward)
10.0x
Gross Margin
74.1%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of INVA are excluded.

TickerCompanyMkt CapStockRankSignal
INVAInnoviva, Inc.(you)$1.7B97STRONG BUY
HRMYHarmony Biosciences Holdings, Inc.$2.1B99STRONG BUY
CPRXCatalyst Pharmaceuticals, Inc.$3.9B99STRONG BUY
RIGLRigel Pharmaceuticals, Inc.$716M98STRONG BUY
CRMDCorMedix Inc.$616M96STRONG BUY
ZVRAZevra Therapeutics, Inc.$799M90STRONG BUY
ABUSArbutus Biopharma Corporation$905M84STRONG BUY
PBYIPuma Biotechnology, Inc.$413M98STRONG BUY
VCELVericel Corporation$2.4B66BUY
HALOHalozyme Therapeutics, Inc.$8.9B90STRONG BUY

Peer medians: ROE -21.3% · P/E 27.3x · Gross margin 44.3%

Innoviva, Inc. (INVA) — Stock Score Summary

Innoviva, Inc. (INVA) has a MoatMap StockRank of 97/100 based on Quality (72/100), Value (74/100), and Momentum (59/100) factor scores. The current signal is STRONG BUY.

Innoviva, Inc. focuses on royalties from respiratory drugs, primarily through its collaboration with GlaxoSmithKline (GSK) on therapies like Relvar/Breo Ellipta and Anoro Ellipta. The company benefits from a stable, long-term revenue stream derived from royalties on blockbuster respiratory medications, minimizing operational and R&D expenditures. It is a unique healthcare company acting primarily as a royalty aggregator, providing exposure to established drug franchises.

Key Financial Metrics

Price$22.20
Market Cap$1.7B
P/E (TTM)3.59
P/E (Forward)10.05
Price/Book1.22
Return on Equity50.7%
Return on Invested Capital21.7%
Debt/Equity24.70
Gross Margin74.1%
Operating Margin40.1%
Revenue Growth10.6%
Free Cash Flow$105M

Innoviva, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Innoviva, Inc.’s (INVA) StockRank?
MoatMap’s StockRank for Innoviva, Inc. (INVA) is 97/100, with a Strong Buy signal. It is a composite of Quality (72), Value (74), and Momentum (59) factor ranks across MoatMap’s 20,000+ stock universe.
Does Innoviva, Inc. have an economic moat?
Innoviva, Inc. (INVA) has a Quality factor score of 72/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Innoviva, Inc. a buy, hold, or sell?
MoatMap’s current signal for Innoviva, Inc. (INVA) is Strong Buy, based on a StockRank of 97/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Innoviva, Inc. in?
Innoviva, Inc. (INVA) operates in the Healthcare sector, specifically the Biotechnology industry (United States).
Browse all ranked stocksINVA deep dive reportAI ChampionsHow we score stocksSense-check another stock